• Novo Nordisk presented a post hoc analysis at EASD 2026 from the STEP UP program assessing Wegovy’s impact on liver health.
• The analysis found most adults with obesity and elevated liver fat moved into the normal range during 72 weeks of treatment.
• Results point to potential use in addressing fatty liver early in obesity, extending Wegovy’s value beyond weight loss.
• Separate late-stage ESSENCE data cited in the release support a broader push for semaglutide in MASH treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010645OMX_____CNEWS_EN_GNW1001275510_en) on October 01, 2026, and is solely responsible for the information contained therein.